Literature DB >> 2700567

Immunological aspects on IDDM in children.

J Ludvigsson.   

Abstract

Diabetes mellitus in childhood is connected to several immunological phenomena which per se do not prove that immunological mechanisms do cause the beta cell destruction, as such mechanisms could be just secondary. However, there is now evidence which strongly supports the autoimmune hypothesis, like the beta-cell destruction in the transplant given from a healthy twin to the diabetic monozygotic co-twin, the effect in newly-diagnosed diabetes of immunosuppression, the passive transfer in experimental animals of an immune process creating diabetes etc. Several facts such as presence of activated T-cells in the insulitis indicate that the cell-mediated immunity is important, while it is still debatable whether humoral factors, and if so which, alone could be responsible for the beta cell destruction. Recently interleukins and other lymphokines have shown to be of great interest as well as the release of free radicals. This knowledge opens new views on the possibility to put an end to or even prevent the beta cell destruction. Rough immunosuppression with cytostatics or cyclosporin has such severe side-effects that such therapy is contra-indicated at least in children. Until more specific therapies are discovered e.g. vaccination with lymphoblasts or blocking the autoantigens with monoclonal antibodies, supportive measures to protect the beta cells may be one practical way.

Entities:  

Mesh:

Year:  1989        PMID: 2700567     DOI: 10.1007/BF02776459

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  35 in total

1.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

2.  Pathologic anatomy of the pancreas in juvenile diabetes mellitus.

Authors:  W Gepts
Journal:  Diabetes       Date:  1965-10       Impact factor: 9.461

3.  Cytokines cause functional and structural damage to isolated islets of Langerhans.

Authors:  T Mandrup-Poulsen; K Bendtzen; J H Nielsen; G Bendixen; J Nerup
Journal:  Allergy       Date:  1985-08       Impact factor: 13.146

4.  Insulin autoantibodies are associated with islet cell antibodies; their relation to insulin antibodies and B-cell function in diabetic children.

Authors:  J Ludvigsson; C Binder; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1988-09       Impact factor: 10.122

5.  Islet morphology in type I diabetes.

Authors:  W Gepts
Journal:  Behring Inst Mitt       Date:  1984-07

6.  Thyroid, gastric, and adrenal autoimmunities associated with insulin-dependent diabetes mellitus.

Authors:  N K Maclaren; W J Riley
Journal:  Diabetes Care       Date:  1985 Sep-Oct       Impact factor: 19.112

7.  Insulin antibodies in diabetic children treated with monocomponent porcine insulin from the onset: relationship to B-cell function and partial remission.

Authors:  J Ludvigsson
Journal:  Diabetologia       Date:  1984-02       Impact factor: 10.122

8.  Islet-cell-surface antibodies in juvenile diabetes mellitus.

Authors:  A Lernmark; Z R Freedman; C Hofmann; A H Rubenstein; D F Steiner; R L Jackson; R J Winter; H S Traisman
Journal:  N Engl J Med       Date:  1978-08-24       Impact factor: 91.245

9.  C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control.

Authors:  J Ludvigsson; L G Heding; Y Larsson; E Leander
Journal:  Acta Paediatr Scand       Date:  1977-03

10.  The external artificial pancreas: an instrument to induce remissions in severe recent juvenile diabetes. Comparison with a preprogrammed insulin infusion system.

Authors:  J Mirouze; J L Selam; T C Pham; A Orsetti
Journal:  Horm Metab Res Suppl       Date:  1979
View more
  1 in total

Review 1.  Therapies to Preserve β-Cell Function in Type 1 Diabetes.

Authors:  Johnny Ludvigsson
Journal:  Drugs       Date:  2016-02       Impact factor: 11.431

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.